Genmab Announces Financial Results for the First Quarter of 2026
7/5 17:02
May 7, 2026 Copenhagen, Denmark; Interim Report for the Three Months Ended March 31, 2026 Highlights Genmab revenue increased 25% compared to the first three months of 2025, to $896 million FDA approved an sBLA to remove the recommendation for 24-hour hospitalization for patients with third line...